摘要
目的探讨RIPK1表达与乳腺癌新辅助治疗后Miller-Payne评分的相关性及对化疗敏感性的影响。方法采用免疫组化法检测RIPK1在乳腺癌组织中的表达;应用Western blot法检测乳腺癌不同细胞系中RIPK1的表达,并构建敲低细胞株;使用CCK-8、克隆形成和流式细胞术检测敲低RIPK1表达对细胞化疗敏感性的影响。结果RIPK1在耐药组中高表达率为69.0%(20/29),在敏感组中高表达率为42.9%(15/35),RIPK1蛋白表达与Miller-Payne评分显著相关(P=0.037)。Western blot实验显示不同细胞系中RIPK1表达量不同,构建RIPK1敲低细胞株并使用不同浓度药物诱导凋亡,CCK-8、克隆形成和流式细胞术显示,与对照组相比,敲低RIPK1表达后细胞存活率下降、凋亡率升高,克隆形成率下降。结论低水平RIPK1可提高乳腺癌细胞对化疗的敏感性。
Purpose To explore the association of RIPK1 expression and Miller-Payne score after neoadjuvant therapy and its effect on chemotherapy sensitivity in breast cancer.Methods Immunohistochemistry(IHC)was used to detect RIPK1 in paraffin samples from breast cancer.Western blot was used to detect the expression of RIPK1 in different breast cancer cell lines,knockdown cell lines were constructed.CCK-8,clone formation experiment and flow cytometry were used to detect the effect of knockdown RIPK1 on the sensitivity of cells to chemotherapy.Results The IHC results showed that the high expression rate of RIPK1 was 69.0%(20/29)in the resistant group and 42.9%(15/35)in the sensitive group,and the expression of RIPK1 was significantly correlated with the Miller-Payne score(P=0.037).Western blot assay showed that the expression levels of RIPK1 were different in different cell lines,RIPK1 knockdown cell lines were constructed and induced apoptosis using different concentrations of drugs.CCK-8,clone formation experiment and flow cytometry showed that knockdown of RIPK1 could decrease the cell survival rate,increase the apoptosis rate and decrease the colony formation rate compared with the control group.Conclusion Knockdown of RIPK1 promotes chemotherapy sensitivity of breast cancer cells.
作者
石亭亭
曲燕
王娟如
罗军
罗文武
郭欠影
赵敏
吴正升
SHI Tingting;QU Yan;WANG Juanru;LUO Jun;LUO Wenwu;GUO Qianying;ZHAO Min;WU Zhengsheng(Department of Pathology,School of Basic Medical Sciences,Anhui Medical University,Hefei 230032,China;Department of Pathology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China;Department of Pain Clinic,Haitang Community Hospital,Hefei 230001,China;Department of Pathology,the Second People’s Hospital of Hefei,Hefei 230011,China)
出处
《临床与实验病理学杂志》
CAS
北大核心
2024年第11期1148-1153,共6页
Chinese Journal of Clinical and Experimental Pathology
基金
国家自然科学基金(81972472)
